Bluefish recruits key competence for the future

The Swedish specialty pharma company Bluefish is in the process of building up an organization with some of the most exciting and dynamic talent in the Swedish pharmaceutical market. In September, four new people will assume important roles at Bluefish.

“With new competence in the company, we plan to work this fall on extending our product portfolio even further. A natural step in our development will be to participate at an earlier stage in the value chain of product development. This allows us to lay a solid ground for a profitable market position in the long run,” says CEO Karl Karlsson.

Susanna Urdmark, a former manager for Handelsbanken’s pharmaceutical fund, will now be in charge of developing a competitive product portfolio with a solid growth potential. She will identify new ways to create value.

“The market for generics will see strong growth in the next few years as many pharmaceuticals with significant value to patients lose their patents. There are great opportunities for developing unique preparations of generic substances at a limited investment level and with a reasonable risk profile,” says Susanna Urdmark. “We have already established partnerships with research companies on the Indian market who offer this kind of competence.”

As an important step in establishing a new sales organization, Bluefish has also hired Johan Florin as the head of marketing and sales. Johan Florin is the chairman of the Association for Generic Pharmaceuticals, and has most recently been employed at Merck NM where he was the Nordic head of marketing and sales.

Bluefish is also filling a regulatory function with the recruitment of Catharina Selander who most recently came from Krka, and Dana Enkusson from AstraZeneca. Both have extensive experience in registering pharmaceuticals on the European market. Internal competence within the regulatory area is decisive for the company’s new expansive phase.

“We have succeeded in recruiting incredibly knowledgeable and sought-after employees who will now be cornerstones in Bluefish’s future development. I am proud that they have chosen Bluefish,” says CEO Karl Karlsson.

For more information: Karl Karlsson, CEO, tel 08-679 50 70

Bluefish Pharmaceuticals AB is a Swedish specialty pharma company that buys or licenses the rights to manufacture pharmaceuticals, mainly generic products. Low prices are maintained through efficient production and distribution. Bluefish has a wholly-owned subsidiary in Chennai, India focused on product development and production. The company is owned by its founder Karl Karlsson, and a number of funds and private investors.